Premier’s Hereditary Cancer Test analyzes the most relevant genes for mutations that could increase your patient’s risk for breast, colorectal, melanoma, ovarian, pancreatic, prostate, stomach, and uterine cancers.
* Please note that research and screening guidelines for genes associated with hereditary prostate cancer are still in their early stages. It is part of the service to keep you updated if any information related to your results changes.
** Only positions known to impact cancer risk analyzed: CDK4: only chr12:g.58145429-58145431 (codon 24) analyzed, EPCAM: only large deletions and duplications including 3’ end of the gene analyzed, GREM1: only duplications in the upstream regulatory region analyzed, MITF: only chr3:g.70014091 (including c.952G>A) analyzed, POLD1: only chr19:g.50909713 (including c.1433G>A) analyzed, POLE: only chr12:g.133250250 (including c.1270C>G analyzed.
*** PMS2: Exons 12-15 not analyzed.